scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
scPharmaceuticals reported strong Q3 2024 results with FUROSCIX net revenue of $10.0 million, up 164% from Q3 2023 and 24% from Q2 2024. Key achievements include FDA approval for NYHA Class IV patients, positive PK/PD data for Autoinjector program, and completion of $175 million financing. The company filled approximately 10,800 FUROSCIX doses (+16% QoQ) and expanded to 3,100 unique prescribers. However, gross-to-net discount increased to 15.7% from 8% in Q2. The company reported a net loss of $35.1 million ($0.75 per share), with $91.5 million cash on hand as of quarter-end.
scPharmaceuticals ha riportato risultati solidi per il terzo trimestre del 2024, con un fatturato netto di FUROSCIX di 10,0 milioni di dollari, in aumento del 164% rispetto al terzo trimestre del 2023 e del 24% rispetto al secondo trimestre del 2024. I principali risultati includono l'approvazione della FDA per i pazienti della Classe IV NYHA, dati positivi di PK/PD per il programma di autoiniettori e il completamento di un finanziamento di 175 milioni di dollari. L'azienda ha distribuito circa 10.800 dosi di FUROSCIX (+16% rispetto al trimestre precedente) ed è cresciuta fino a 3.100 medici unici prescrittori. Tuttavia, lo sconto lordo-netto è aumentato al 15,7% rispetto all'8% del secondo trimestre. L'azienda ha riportato una perdita netta di 35,1 milioni di dollari (0,75 dollari per azione), con 91,5 milioni di dollari di liquidità a disposizione al termine del trimestre.
scPharmaceuticals reportó resultados sólidos en el tercer trimestre de 2024, con ingresos netos de FUROSCIX de 10.0 millones de dólares, un aumento del 164% en comparación con el tercer trimestre de 2023 y del 24% frente al segundo trimestre de 2024. Los logros clave incluyen la aprobación de la FDA para pacientes de Clase IV NYHA, datos positivos de PK/PD para el programa de autoinyectores y la finalización de un financiamiento de 175 millones de dólares. La compañía distribuyó aproximadamente 10,800 dosis de FUROSCIX (+16% respecto al trimestre anterior) y se expandió a 3,100 prescriptores únicos. Sin embargo, el descuento bruto-neto aumentó al 15.7% desde el 8% en el segundo trimestre. La compañía reportó una pérdida neta de 35.1 millones de dólares (0.75 dólares por acción), con 91.5 millones de dólares en efectivo disponible al final del trimestre.
scPharmaceuticals는 2024년 3분기 강력한 실적을 보고했으며, FUROSCIX의 순수익은 1천만 달러로 2023년 3분기 대비 164% 증가하고 2024년 2분기 대비 24% 증가했습니다. 주요 성과로는 NYHA 클래스 IV 환자에 대한 FDA 승인, 자가주입기 프로그램에 대한 긍정적인 PK/PD 데이터 및 1억 7500만 달러 금융 조달 완료가 있습니다. 이 회사는 약 10,800개의 FUROSCIX 용량을 공급했으며(+16% 분기 대비) 3,100명의 고유 처방의사로 확대했습니다. 그러나 총순이익의 할인율은 2분기 8%에서 15.7%로 증가했습니다. 이 회사는 분기말 기준으로 3,510만 달러(주당 0.75 달러)의 순손실을 보고했으며, 현금은 9,150만 달러를 보유하고 있습니다.
scPharmaceuticals a annoncé de solides résultats pour le troisième trimestre 2024, avec un chiffre d'affaires net de FUROSCIX s'élevant à 10,0 millions de dollars, soit une augmentation de 164 % par rapport au troisième trimestre 2023 et de 24 % par rapport au deuxième trimestre 2024. Parmi les principales réalisations figurent l'approbation de la FDA pour les patients de classe IV NYHA, des données PK/PD positives pour le programme d'auto-injecteur et l'achèvement d'un financement de 175 millions de dollars. L'entreprise a distribué environ 10 800 doses de FUROSCIX (+16 % par rapport au trimestre précédent) et s'est élargie à 3 100 prescripteurs uniques. Toutefois, la remise brut-net a augmenté à 15,7 % contre 8 % au 2e trimestre. L'entreprise a enregistré une perte nette de 35,1 millions de dollars (0,75 dollar par action), avec 91,5 millions de dollars de liquidités disponibles à la fin du trimestre.
scPharmaceuticals berichtete über starke Ergebnisse im 3. Quartal 2024, mit einem Nettoumsatz von FUROSCIX in Höhe von 10,0 Millionen Dollar, was einem Anstieg von 164% im Vergleich zum 3. Quartal 2023 und von 24% im Vergleich zum 2. Quartal 2024 entspricht. Zu den wichtigsten Erfolgen gehören die FDA-Zulassung für Patienten der NYHA-Klasse IV, positive PK/PD-Daten für das Autoinjektor-Programm und der Abschluss einer Finanzierung in Höhe von 175 Millionen Dollar. Das Unternehmen lieferte etwa 10.800 FUROSCIX-Dosen (+16% im Vergleich zum Vorquartal) und erweiterte sich auf 3.100 einzigartige Verschreiber. Der Bruttobetrag, der von den Nettobeträgen abgezogen wurde, stieg jedoch von 8% im 2. Quartal auf 15,7%. Das Unternehmen berichtete von einem Nettoverlust von 35,1 Millionen Dollar (0,75 Dollar pro Aktie) bei 91,5 Millionen Dollar Bargeld zum Quartalsende.
- Net revenue growth of 164% YoY to $10.0 million
- 16% QoQ increase in FUROSCIX doses filled to 10,800
- FDA approval expansion to include NYHA Class IV patients
- Secured $175 million financing expected to fund through profitability
- 5.5% price increase implemented for FUROSCIX
- 14% increase in unique prescribers to 3,100
- Net loss increased to $35.1 million from $15.6 million YoY
- Gross-to-net discount nearly doubled to 15.7% from 8% QoQ
- Selling, general and administrative expenses increased 51% YoY to $21.3 million
Insights
The Q3 results demonstrate strong commercial momentum for FUROSCIX with
However, increased gross-to-net discount of
The FDA approval for NYHA Class IV patients significantly expands FUROSCIX's addressable market to include the most severe heart failure cases. The pending sNDA for CKD indication (PDUFA date March 2025) represents another major market opportunity, as many heart failure patients have concurrent CKD. The positive PK/PD data for the autoinjector program suggests potential improvements in drug delivery efficiency.
The growing prescriber base (3,100 unique prescribers) and IDN/hospital system adoption (14 systems) indicate increasing clinical acceptance. The product's ability to treat congestion outside hospital settings could drive significant healthcare cost savings.
Generated 3Q 2024 net FUROSCIX® revenue of
Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients
Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program
Completed
Company to host investor conference call and webcast today, Wednesday, November 13th, at 4:30pm ET
BURLINGTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
Business Update
- For the third quarter ended September 30, 2024, scPharmaceuticals reports:
- Net FUROSCIX revenue of
$10.0 million , representing a24% increase from the second quarter of 2024 - Approximately 10,800 FUROSCIX doses filled, representing a
16% increase from the second quarter of 2024 - Approximately 6.8 doses per prescription, up from 6.3 in the second quarter of 2024
- Approximately 3,100 unique prescribers from launch until the end of the third quarter of 2024, up approximately
14% from the end of the second quarter of 2024 - Gross-to-net discount of
15.7% in the third quarter of 2024, compared to8% in the second quarter of 2024 - Received direct purchases from 14 Integrated Delivery Networks (IDNs)/hospital systems year to date
- Price increase of FUROSCIX by
5.5% at the end of September of 2024 expected to have a positive impact on product revenues
- Net FUROSCIX revenue of
- Transformative Financing Through Profitability: In August 2024, scPharmaceuticals announced concurrent equity, debt and royalty financings totaling up to
$175 million . The transactions were comprised of a$50 million equity financing with leading life science investors, as well as both a$75 million senior debt facility and$50 million in a synthetic royalty agreement with Perceptive Advisors. The combined$175 million is anticipated to fund scPharmaceuticals’ operations through expected profitability. - NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart Association Class IV chronic heart failure patients.
- PK/PD Data for Autoinjector: In August 2024, scPharmaceuticals announced positive PK/PD data that met all primary and secondary endpoints. scPharmaceuticals is continuing to progress towards its targeted submission of a Supplemental New Drug Application (sNDA) to the FDA by the end of January 2025.
- sNDA FUROSCIX Filing in Chronic Kidney Disease (CKD): In July 2024, scPharmaceuticals announced that the FDA has accepted for filing the Company’s sNDA seeking to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with CKD. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025.
“The continued growth of FUROSCIX net revenue is encouraging, particularly as we have begun to see increased penetration into the Class IV chronic heart failure patient population following the FDA`s approval of the FUROSCIX expanded indication in August. We anticipate the expansion of the sales force that we completed in late September to have a potentially meaningful impact on sales moving forward. In addition, we saw a significant increase in the FUROSCIX purchase flow from IDNs and hospital systems,” stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals. “We remain committed to our FUROSCIX lifecycle initiatives, including the development of our Autoinjector. The Autoinjector is anticipated to meaningfully reduce cost of goods sold over the medium-to-long-term. We continue to advance our pre-launch activities in anticipation of our PDUFA target action date on March 6, 2025, in patients with fluid overload due to CKD. In preparation for the potential indication expansion, we have conducted in depth market research, identified key opinion leaders, and have incorporated high impact nephrology offices that are already treating heart failure patients that also have CKD into our call plan.”
Third Quarter 2024 Financial Results
Product revenues were
Research and development expenses were
Selling, general and administrative expenses were
scPharmaceuticals reported a net loss of
scPharmaceuticals ended the third quarter of 2024 with
As of September 30, 2024, scPharmaceuticals’ total shares outstanding was 50,040,134.
Conference call and webcast information
scPharmaceuticals’ management will host a conference call and webcast to review the Company’s third quarter 2024 results today, Wednesday, November 13th, at 4:30 p.m. EST. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13749995.
To access the Call me™ feature, which avoids having to wait for an operator, click here.
The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous use
FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure.
IMPORTANT SAFETY INFORMATION
FUROSCIX is contraindicated in patients with anuria, patients with a history of hypersensitivity to furosemide, any component of the FUROSCIX formulation or medical adhesives and in patients with hepatic cirrhosis.
Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.
Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.
Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms.
The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
For more details, please read the full Prescribing Information at FUROSCIX.com/prescribing-information.pdf and Instructions for Use at FUROSCIX.com/instructions-for-use.pdf.
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the development and commercialization of products, such as the Autoinjector, that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs and costs of goods sold; our commercial strategy for FUROSCIX and anticipated sales; the PDUFA target action date of March 6, 2025 related to the NDA seeking to expand the FUROSCIX indication to include the treatment of fluid overload in CKD; the potential submission of the sNDA with PK/PD Data for the Autoinjector; our ability to fund the Company through expected profitability; participation in upcoming events and presentations; and the timing of any of the foregoing. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to support submission of sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company’s operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
Nick@GilmartinIR.com
| scPharmaceuticals Inc. | |||||||||||||||
| Unaudited Consolidated Statements of Operations | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| THREE MONTHS ENDED SEPTEMBER 30, | NINE MONTHS ENDED SEPTEMBER 30, | ||||||||||||||
| 2023 | 2024 | 2023 | 2024 | ||||||||||||
| Product revenues, net | $ | 3,796 | $ | 10,026 | $ | 7,497 | $ | 24,182 | |||||||
| Operating expenses: | |||||||||||||||
| Cost of product revenues | $ | 1,079 | $ | 3,311 | $ | 2,038 | $ | 7,396 | |||||||
| Research and development | 3,421 | 3,541 | 8,471 | 8,944 | |||||||||||
| Selling, general and administrative | 14,135 | 21,320 | 37,127 | 56,275 | |||||||||||
| Total operating expenses | 18,635 | 28,172 | 47,636 | 72,615 | |||||||||||
| Loss from operations | (14,839 | ) | (18,146 | ) | (40,139 | ) | (48,433 | ) | |||||||
| Loss on extinguishment of debt | - | (13,032 | ) | - | (13,032 | ) | |||||||||
| Change in fair value of term loan | - | (2,954 | ) | - | (2,954 | ) | |||||||||
| Change in fair value of revenue purchase and sale liability | - | (1,830 | ) | - | (1,830 | ) | |||||||||
| Other (expense) income | (36 | ) | 1,804 | 1,193 | 3,587 | ||||||||||
| Interest income | 1,301 | 903 | 3,979 | 2,444 | |||||||||||
| Interest expense | (2,060 | ) | (1,850 | ) | (6,031 | ) | (6,085 | ) | |||||||
| Net loss | $ | (15,634 | ) | $ | (35,105 | ) | $ | (40,998 | ) | $ | (66,303 | ) | |||
| Net loss per share, basic and diluted | $ | (0.41 | ) | $ | (0.75 | ) | $ | (1.07 | ) | $ | (1.60 | ) | |||
| Weighted—average common shares outstanding, basic and diluted | 38,760,895 | 46,558,484 | 38,421,676 | 41,516,917 | |||||||||||
| scPharmaceuticals Inc. | ||||||||
| Unaudited Consolidated Balance Sheet Data | ||||||||
| (in thousands) | DECEMBER 31, | SEPTEMBER 30, | ||||||
| 2023 | 2024 | |||||||
| Cash, cash equivalents and investments | $ | 76,013 | $ | 91,484 | ||||
| Working capital | 79,804 | 108,065 | ||||||
| Total assets | 94,479 | 125,069 | ||||||
| Term loan | 38,811 | 51,099 | ||||||
| Revenue purchase and sale liability | — | 26,830 | ||||||
| Accumulated deficit | (281,346 | ) | (347,649 | ) | ||||
| Total stockholders’ equity | 37,218 | 30,709 | ||||||
FAQ
What was SCPH's Q3 2024 FUROSCIX revenue?
How many FUROSCIX doses did SCPH fill in Q3 2024?
What was SCPH's net loss per share in Q3 2024?
When is SCPH's PDUFA date for the CKD indication?
